The Catholic University of Korea Industry-academic Cooperation Foundation

Catholic University Industry Academic Cooperation Foundation

Hanlim Pharmaceutical Co., Ltd.

Curogen Technology Co., Ltd.

Korea Research Institute of Bioscience and Biotechnology

Bifido Co., Ltd.

The Catholic University of Korea Industry-academic Cooperation Foundation, Catholic Univ. of Korea Songeui Campus

Catholic University Academic Cooperation Foundation

The Catholic University of Korea Industry-academic Corporation Foundation

The Catholic University of Korea Industry-academic

Mi-La Cho

Seon-Yeong Lee

Min-Jung Park

Sung-Hwan Park

Hye-Jin Son

Sung-Hee Lee

Dong-Yun Shin

Eun-Kyung Kim

Chul-Woo Yang

Jong-Young Choi

Jae-Kyung Kim

Hyeon-Beom Seo

Joo-Yeon Jhun

Eun-Ji Yang

Hye-Jwa Oh

Jun-Geol Ryu

Young-Mee Moon

Seung-Hun Lee

Seung-Ki Kwok

Eun Kyung Kim

Jin-Ha Park

Eun-Jung Lee

Geun-Hyeog Lee

Chang Woo Lee

Eun-Young Kwak

Jae-yoon Ryu

Eun Ji Yang

Ho Jun Kim

Young Woo Park

Ji-Won Kim

Ji Hyun Park

Ho Youn Kim

Yun-Ju Woo

Jun-Ki Min

Jin-Sil Park

Jin-Kwan Lee

Kyoung-Woon Kim

Hee-yeon Kim

Geun Eog Ji

Joon-Goo Jung

Myung-ho Sohn

Seok-Jung Kim

Jae Won Jeon

Byong-Sun Choi

Young-Soon Jang

Bin Kwon

Chul Woo Yang

Byung Ha Chung

Min Jung Park

Ye-Been Yim

Se-Young Kim

Keun-Hyung Cho

Se-Wan Park

Ji-Hun Moon

Jeong-hee Jeong

Su-Jin Moon

Jae-Kyeong Byun

Byung-Ha Chung

Yeong-Mi Mun

Hyang-Suk Rhim

Seong-Hyeok Park

Young-Ok Jung

Jennifer Lee

Ji-Hyeon Ju

Hui Fang

Yunju Jeong

Yang-Mi Her

Hye In Choi

Chul- Woo Yang

The present invention relates to a composition for preventing or treating transplantation rejection or a transplantation rejection disease, comprising a novel compound and a calcineurin inhibitor. A co-administration of the present invention 1) reduces the activity of pathogenic Th1 cells or Th17 cells, 2) increases the activity of Treg cells, 3) has an inhibitory effect against side effects, such as tissue damage, occurring in the sole administration thereof, 4) inhibits various pathogenic pathways, 5) inhibits the cell death of inflammatory cells, and 6) increases the activity of mitochondria, in an in vivo or in vitro allogenic model, a transplantation rejection disease model, a skin transplantation model, and a liver-transplanted patient, and thus inhibits transplantation rejection along with mitigating side effects possibly occurring in the administration of a conventional immunosuppressant alone. Thus, the present invention may be used in the field of pharmaceutics relating to transplantation rejection or various immune disorders possibly occurring after transplantation.

Composition for preventing and treating transplant rejection or transplant rejection diseases, comprising novel compound and calcineurin inhibitor

The present disclosure relates to a method for inhibiting a STAT3 activity comprising administering SSu72 protein.

Method for inhibiting STAT3 activity comprising administering Ssu72

The present disclosure relates to a method of preventing rheumatoid arthritis comprising administering a polynucleotide encoding Ssu72.

Method of preventing rheumatoid arthritis comprising administering polynucleotide encoding SSU72

The present invention relates to a mesenchymal stem cell having immunomodulatory activity and a preparation method therefor and, more specifically, to: a rapamycin-treated mesenchymal stem cell having immunomodulatory activity, which expresses any one or more cell surface factors selected from the group consisting of CCR1, CCR2, CCR3, CCR4, CCR7, CCR9 and CXCR4; a cell therapy composition comprising the mesenchymal stem cell, for preventing or treating immune disorders; and a preparation method for the mesenchymal stem cell having immunomodulatory activity. The rapamycin-treated mesenchymal stem cell having immunomodulatory activity, according to the present invention, has increased expression of IDO, TGF-&#x3b2; and IL-10 which are factors having immunomodulatory activity, has decreased expression of Phospho-mTOR, Rictor and Ractor which are signal transduction factors of mTOR, and has increased expression, in the cell, of autophagic inducer Beclin1, ATG5, ATG7, LC3I or LCII. If this cell is used as a cell therapy in individuals having immune disorders, it is possible to effectively treat immune disorders.

MTOR/STAT3 signal inhibitor-treated mesenchymal stem cell having immunomodulatory activity, and cell therapy composition comprising same, for preventing or treating immune disorders

The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of IL-17 and TNF-&#x3b1;, which are inflammatory cytokines, increases the activity of regulatory T cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune diseases. Accordingly, the biguanide-based derivative compound can be usefully used as an immunosuppressant or a pharmaceutical composition capable of preventing or treating various immune diseases, such as autoimmune diseases, inflammatory diseases, and transplant rejection, caused by the dysregulation of immune responses.

Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing biguanide derivative compound as active ingredient

Provided is a composition containingfor alleviating, preventing or treating rheumatoid arthritis. TheATT newly isolated according to the present invention is useful as a rheumatoid arthritis medicine or a probiotic material for alleviating rheumatoid arthritis owing to potent efficacy in treating rheumatoid arthritis.

Composition containingfor alleviating, preventing or treating rheumatoid arthritis

Provided is a novel compound capable of effectively preventing and treating immune diseases and a use thereof. The novel compound of the present subject matter has effects of inhibiting the production of inflammatory cytokines, increasing the activity of regulatory T cells having immunoregulatory functions, inhibiting the production of auto-antibodies to regulate excessive immune responses, and inhibiting the differentiation of osteoclasts, and thus can be used for treating immune diseases, such as autoimmune disease, inflammatory disease, and transplant rejection diseases, which are caused by abnormal regulation of various kinds of immune response.

Compound having immune disease treatment effect and use thereof

The present invention relates to a composition comprising metformin as an active ingredient for preventing or treating inflammatory bowel disease. The metformin compound or the metformin-etanercept (product name: Enbrel) composite according to the present invention may have excellent effects of maintaining the thickness of the small intestine and length of the large intestine normal, inhibiting or decreasing the activity of IL-17 and TNF-a, and promoting or increasing the activity of IFNr, and therefore can be effectively used as a pharmaceutical composition for preventing or treating autoimmune diseases including inflammatory bowel disease.

Composition comprising metformin as active ingredient for preventing or treating inflammatory bowel disease

The present invention relates to a composition for preventing or treating an autoimmune disease comprising, as an active ingredient, PINK1 protein or polynucleotide encoding the same. The PINK1 protein according to the present invention inhibits the activity of Th17, promotes the activity of a regulatory T cell (Treg), and increases autophagy in Treg cells, thereby controlling excessive immune responses. Therefore, the PINK1 protein can be effectively used as a pharmaceutical composition or an immunosuppressant, which is capable of preventing or treating an autoimmune disease, such as arthritis, and the like, caused by dysregulation of various kinds of immune responses.

Composition for preventing or treating autoimmune disease, comprising, as active ingredient, PINK1 protein or polynucleotide encoding same

The daurinol compound according to the present invention exhibits excellent therapeutic effects on arthritis and inflammatory bowel diseases by having an excellent activity in inhibiting the generation of IL-17 and TNF-&#x3b1;, which are inflammatory cytokines causing inflammation, and can alleviate transplant rejection by inhibiting the proliferation of alloreactive T cells and increasing regulatory T cells; therefore, the daurinol compound according to the present invention can be used as a pharmaceutical composition capable of treating and preventing immune diseases. In addition, being a natural substance derived from the Mongolian medicinal plantor, the daurinol compound according to the present invention does not cause cytotoxicity and thus may be used as a composition for a functional health food capable of preventing and remedying immune diseases.

Composition for treating immune diseases containing daurinol compound as active ingredient

The present invention relates to a method and a kit for monitoring an immune status after transplant. The kit for monitoring an immune status after transplant and the method for monitoring an immune status of an individual after transplant as provided in the present invention make it easy and accurate to determine an immune status in the individual after transplant and thus have an effect of reducing overuse of an immunosuppressive agent prescribed after transplant and also have an effect of conveniently managing an immune status of each patient.

Kit for monitoring immune status after transplant and method for monitoring immune status using same

The present invention provides a method for preventing or treating osteoarthritis comprising administrating rebamipide or a pharmaceutical composition comprising rebamipide as an active ingredient and a pharmaceutically acceptable carrier to a subject in need thereof. The pharmaceutical composition may be for oral administration, for example an oral solid dosage form of a tablet or capsule form. The pharmaceutical composition may be formulated into a unit dosage form suitable for orally administering rebamipide in a dose ranging from 0.5 to 50 mg/kg, preferably from 0.6 to 6 mg/kg.

Pharmaceutical composition for the prevention or treatment of osteoarthritis containing rebamipide as an active ingredient

The present invention relates to a composition containing PIAS3 as an active ingredient for the prevention or treatment of cancer or immune disease. More specifically, the present invention relates to a composition containing the PIAS3 gene or an expressing protein thereof as an active ingredient for the prevention or treatment of cancer or immune disease, to an immunosuppressant composition, to a method for reducing or inhibiting undifferentiated T cells into Th17 cells using the PIAS3 gene or an expressing protein thereof, and to a method for activating regulatory T cells.

Composition containing PIAS3 as an active ingredient for preventing or treating cancer or immune disease

The present invention relates to an anti-inflammatory composition using the antibody specifically binding to CD93 or its soluble fragment, and a diagnostic method and a diagnostic kit for inflammatory disease using CD93 or its soluble fragment specific antibody or aptamer.

CD93 or use of soluble fragment thereof

Growing community of inventors

Seoul, South Korea

Mi-La Cho